International Endeavors (OTC: IDVV) this morning said that it has signed a memorandum of understanding (MOU) with Kubby Cryogenics, Inc. Per the agreement, Kubby Cryogenics will seek to patent medical grade cannabis strains that are genetically profiled to treat specific diseases. The agreement also states that Steve Kubby will immediately become CEO of International Endeavors. Kubby Cryogenics has assembled a team of top scientists and geneticists to continue developing the company’s proprietary cryogenics products. “We will create a dispensary system for legal medical cannabis states standardizing the patient centered, consultation approach while presenting an enticing line of Adult Use products featuring a patent pending menu of powerful strains and pure, all natural, solvent-less concentrate products,” International Endeavors incoming CEO Steve Kubby stated in the news release.
To view the full press release, visit: http://cnw.fm/Mgj72
About International Endeavors Corporation
International Endeavors Corporation is a company focused on biomedical uses of non-psychoactive cannabis based products for the treatment of a wide variety of illnesses. Through a unique patent pending Cryogenic process, the company can process different unique medical grade cannabis strains that are genetically profiled to treating specific diseases. www.internationalendeavorscorp.com
More from CannabisNewsBreaks
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com